Related Experiment Video
Updated: Jun 1, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
Alexander Shimabukuro-Vornhagen1, Achim Rothe, Lucia Nogova
1Department I of Internal Medicine, University Hospital Cologne, Kerpener Strasse 62, D-50924 Köln, Germany. michael.bergwelt@uk-koeln.de.
Introduction:
In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL+ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders.
Case Presentation:
We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib.
Conclusion:
This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL+ chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia.
